HM myeloma cell lines

 

---

Study Field: Multiple Myeloma || Number of samples: 42
Number of subgroup(s): 1 [1: Human myeloma cell lines (n=42)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s): Moreaux J et al. A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines. Haematologica. 2011 Apr;96(4):574-82. PMID: 21173094

MS human plasma cell differentiation 2

---

Study Field: Plasma cell differentiation || Number of samples: 62
Number of subgroup(s): 10 [1: Naïve B cells (n=5); 2: Centroblasts (n=4); 3: Centrocytes (n=4); 4: Memory B cells (n=5); 5: CD20highCD38neg B cells (n=5); 6: Preplasmablasts (n=5); 7: Plasmablasts (n=5); 8: Plasmablasts normoxia (n=2); 9: Plasmablasts hypoxia (n=2); 10: Early plasma cells (n=5); 11: Early plasma cells infection ctrl (n=5); 12: Early plasma cells infection klf4 (n=5); 13: Long lived plasma cells (n=5); 14: Bone marrow plasma cells (n=5)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s):

• Jourdan et al., Leukemia. 2014 Feb 7. doi: 10.1038/leu.2014.61
• Jourdan et al., J Immunol. 2011 Oct 15;187(8):3931-41.
• Jourdan et al., Blood. 2009 Dec 10;114(25):5173-81.
• Caron G et al., J Immunol. 2009 Jun 15;182(12):7595-602.

HM normal cells and myeloma

---

Study Field: Multiple Myeloma || Number of samples: 279
Number of subgroup(s): 12 [1: Naïve B cells (n=5); 2: Centroblasts (n=4); 3: Centrocytes (n=4); 4: Memory B cells (n=5); 5: CD20highCD38neg B cells (n=5); 6: Preplasmablasts (n=5); 7: Plasmablasts (n=5); 8: Early plasma cells (n=5); 9: Long lived plasma cells (n=5); 10: Bone marrow plasma cells (n=5); 11: Multiple Myeloma sample (n=206); 12: Multiple myeloma cell lines (n=25)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s): undefined.

Human plasma cell differentiation 2

---

Study Field: Plasma cell differentiation || Number of samples: 48
Number of subgroup(s): 10 [1: Naïve B cells (n=5); 2: Centroblasts (n=4); 3: Centrocytes (n=4); 4: Memory B cells (n=5); 5: CD20highCD38neg B cells (n=5); 6: Preplasmablasts (n=5); 7: Plasmablasts (n=5); 8: Early plasma cells (n=5); 9: Long lived plasma cells (n=5); 10: Bone marrow plasma cells (n=5)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s):

• Jourdan et al., Leukemia. 2014 Feb 7. doi: 10.1038/leu.2014.61
• Jourdan et al., J Immunol. 2011 Oct 15;187(8):3931-41.
• Jourdan et al., Blood. 2009 Dec 10;114(25):5173-81.
• Caron G et al., J Immunol. 2009 Jun 15;182(12):7595-602.

Human plasma cell differentiation GCRMA unlogged

---

Study Field: Plasma cell differentiation || Number of samples: 38
Number of subgroup(s): 8 [1: Naïve B cells (n=5); 2: Centroblasts (n=4); 3: Centrocytes (n=4); 4: Memory B cells (n=5); 5: Preplasmablasts (n=5); 6: Plasmablasts (n=5); 7: Early plasma cells (n=5); 8: Bone marrow plasma cells (n=5)]
Chip: Affy U133P2 || Normalization: GCRMA, data are unlogged

---

Citation(s):

• Jourdan et al., J Immunol. 2011 Oct 15;187(8):3931-41.
• Jourdan et al., Blood. 2009 Dec 10;114(25):5173-81.
• Caron G et al., J Immunol. 2009 Jun 15;182(12):7595-602.

•  

Human plasma cell differentiation GCRMA

---

Study Field: Plasma cell differentiation || Number of samples: 38
Number of subgroup(s): 8 [1: Naïve B cells (n=5); 2: Centroblasts (n=4); 3: Centrocytes (n=4); 4: Memory B cells (n=5); 5: Preplasmablasts (n=5); 6: Plasmablasts (n=5); 7: Early plasma cells (n=5); 8: Bone marrow plasma cells (n=5)]
Chip: Affy U133P2 || Normalization: GCRMA, data are in log2 scale

---

Citation(s):

• Jourdan et al., J Immunol. 2011 Oct 15;187(8):3931-41.
• Jourdan et al., Blood. 2009 Dec 10;114(25):5173-81.
• Caron G et al., J Immunol. 2009 Jun 15;182(12):7595-602.

HM Myeloma Microenvironment

---

Study Field: Multiple Myeloma Microenvironment || Number of samples: 27
Number of subgroup(s): 5 [1: Bone marow stromal cells (n=5); 2: Osteoclast cells (n=7); 3: CD14 positive cells (n=5); 4: CD15 positive cells (n=5); 5: CD3 positive cells (n=5)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s): undefined.

HM Myeloma 1

---

Study Field: Multiple Myeloma || Number of samples: 236
Number of subgroup(s): 3 [1: Bone marrow plasma cells (n=5); 2: Multiple Myeloma sample (n=206); 3: Multiple myeloma cell lines (n=25)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)

---

Citation(s): undefined.

Lenz Lymphoma

---

Study Field: Diffuse large B cell lymphoma (n=420) || Number of samples: 420
Number of subgroup(s): 1 [1: Diffuse large B cell lymphoma(n=420)]
Chip: Affy U133P2 || Normalization: MAS5 (scaling value: 500)
--------------------------------------
Survival data: OAS, OAS_DAYS
Clinical data: Age, LDH_Ratio (lactate deshydrogenase), Number_of_extranodal_sites, Clinical_Stage

---

Citation(s): Lenz G et al. N Engl J Med 2008 Nov 27;359(22):2313-23.

Sanchez Lung

---

Study Field: Human lung tumor (non-small cell lung cancer) || Number of samples: 91
Number of subgroup(s): 2 [1: Controls (n=45); 2: Tumors (n=46)]
Chip: Affy U133P2 || Normalization: RMA

---

Citation(s): Sanchez-Palencia A et al. Int J Cancer 2011 Jul 15;129(2):355-64.